Patrick I. Borgen, MD
Neoadjuvant strategies are underutilized in the treatment of HER2-positive breast cancer, says Patrick Borgen, MD.
, Borgen, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discussed the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.
OncLive: If a patient undergoes testing and it comes back that they have HER2 expression, what are some of the first things that you are thinking about?
: What has been amazing over the last 20 years of my career is how much the view of HER2-positive [disease] has changed. In the pre-HER2 blockade or pre-trastuzumab (Herceptin) era, HER2-postiivty was the worst possible thing that you could get on a biopsy result. One of the first papers that I ever added to my CV was about how bad it was to have HER2-positivity in the absence of treatment. Now…both single- and double-targeting of HER2 have really revolutionized the outcomes.
... to read the full story